Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database
Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with mRCC, but its role and timing are not well understood in the era of immu...
Saved in:
Published in | Current oncology (Toronto) Vol. 31; no. 8; pp. 4704 - 4712 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
01.08.2024
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with mRCC, but its role and timing are not well understood in the era of immunotherapy. The primary objective of this study is to assess outcomes in patients who received ST only, CN followed by ST (CN-ST), and ST followed by CN (ST-CN). The Canadian Kidney Cancer information system (CKCis) database was queried to identify patients with de novo mRCC who received immunotherapy-based ST between January 2014 and June 2023. These patients were classified into three categories as described above. Cox proportional hazards models were used to assess the impact of the timing of ST and CN on overall survival (OS) and progression-free survival (PFS), after adjusting for the International Metastatic RCC Database Consortium (IMDC) risk group, age, and comorbidities. Best overall response and complications of ST and CN for these cohorts were collected. A total of 588 patients were included in this study: 331 patients received ST only, 215 patients received CN-ST, and 42 patients received ST-CN. Patient and disease characteristics including age, gender, performance status, IMDC risk category, comorbidity, histology, type of ST, and metastatic sites are reported. OS analysis favored patients who received ST-CN (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.13-0.68) and CN-ST (HR 0.68, CI 0.47-0.97) over patients who received ST only. PFS analysis showed a similar trend for ST-CN (HR 0.45, CI 0.26-0.77) and CN-ST (HR 0.9, CI 0.68-1.17). This study examined baseline features and outcomes associated with the use and timing of CN and ST using real-world data via a large Canadian real-world cohort. Patients selected to receive CN after ST demonstrated improved outcomes. There were no appreciable differences in perioperative complications across groups. Limitations include the small number of patients in the ST-CN group and residual confounding and selection biases that may influence the outcomes in patients undergoing CN. |
---|---|
AbstractList | Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with mRCC, but its role and timing are not well understood in the era of immunotherapy. The primary objective of this study is to assess outcomes in patients who received ST only, CN followed by ST (CN-ST), and ST followed by CN (ST-CN). The Canadian Kidney Cancer information system (CKCis) database was queried to identify patients with de novo mRCC who received immunotherapy-based ST between January 2014 and June 2023. These patients were classified into three categories as described above. Cox proportional hazards models were used to assess the impact of the timing of ST and CN on overall survival (OS) and progression-free survival (PFS), after adjusting for the International Metastatic RCC Database Consortium (IMDC) risk group, age, and comorbidities. Best overall response and complications of ST and CN for these cohorts were collected. A total of 588 patients were included in this study: 331 patients received ST only, 215 patients received CN-ST, and 42 patients received ST-CN. Patient and disease characteristics including age, gender, performance status, IMDC risk category, comorbidity, histology, type of ST, and metastatic sites are reported. OS analysis favored patients who received ST-CN (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.13-0.68) and CN-ST (HR 0.68, CI 0.47-0.97) over patients who received ST only. PFS analysis showed a similar trend for ST-CN (HR 0.45, CI 0.26-0.77) and CN-ST (HR 0.9, CI 0.68-1.17). This study examined baseline features and outcomes associated with the use and timing of CN and ST using real-world data via a large Canadian real-world cohort. Patients selected to receive CN after ST demonstrated improved outcomes. There were no appreciable differences in perioperative complications across groups. Limitations include the small number of patients in the ST-CN group and residual confounding and selection biases that may influence the outcomes in patients undergoing CN. Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with mRCC, but its role and timing are not well understood in the era of immunotherapy. The primary objective of this study is to assess outcomes in patients who received ST only, CN followed by ST (CN-ST), and ST followed by CN (ST-CN). The Canadian Kidney Cancer information system (CKCis) database was queried to identify patients with de novo mRCC who received immunotherapy-based ST between January 2014 and June 2023. These patients were classified into three categories as described above. Cox proportional hazards models were used to assess the impact of the timing of ST and CN on overall survival (OS) and progression-free survival (PFS), after adjusting for the International Metastatic RCC Database Consortium (IMDC) risk group, age, and comorbidities. Best overall response and complications of ST and CN for these cohorts were collected. A total of 588 patients were included in this study: 331 patients received ST only, 215 patients received CN-ST, and 42 patients received ST-CN. Patient and disease characteristics including age, gender, performance status, IMDC risk category, comorbidity, histology, type of ST, and metastatic sites are reported. OS analysis favored patients who received ST-CN (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.13-0.68) and CN-ST (HR 0.68, CI 0.47-0.97) over patients who received ST only. PFS analysis showed a similar trend for ST-CN (HR 0.45, CI 0.26-0.77) and CN-ST (HR 0.9, CI 0.68-1.17). This study examined baseline features and outcomes associated with the use and timing of CN and ST using real-world data via a large Canadian real-world cohort. Patients selected to receive CN after ST demonstrated improved outcomes. There were no appreciable differences in perioperative complications across groups. Limitations include the small number of patients in the ST-CN group and residual confounding and selection biases that may influence the outcomes in patients undergoing CN.Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with mRCC, but its role and timing are not well understood in the era of immunotherapy. The primary objective of this study is to assess outcomes in patients who received ST only, CN followed by ST (CN-ST), and ST followed by CN (ST-CN). The Canadian Kidney Cancer information system (CKCis) database was queried to identify patients with de novo mRCC who received immunotherapy-based ST between January 2014 and June 2023. These patients were classified into three categories as described above. Cox proportional hazards models were used to assess the impact of the timing of ST and CN on overall survival (OS) and progression-free survival (PFS), after adjusting for the International Metastatic RCC Database Consortium (IMDC) risk group, age, and comorbidities. Best overall response and complications of ST and CN for these cohorts were collected. A total of 588 patients were included in this study: 331 patients received ST only, 215 patients received CN-ST, and 42 patients received ST-CN. Patient and disease characteristics including age, gender, performance status, IMDC risk category, comorbidity, histology, type of ST, and metastatic sites are reported. OS analysis favored patients who received ST-CN (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.13-0.68) and CN-ST (HR 0.68, CI 0.47-0.97) over patients who received ST only. PFS analysis showed a similar trend for ST-CN (HR 0.45, CI 0.26-0.77) and CN-ST (HR 0.9, CI 0.68-1.17). This study examined baseline features and outcomes associated with the use and timing of CN and ST using real-world data via a large Canadian real-world cohort. Patients selected to receive CN after ST demonstrated improved outcomes. There were no appreciable differences in perioperative complications across groups. Limitations include the small number of patients in the ST-CN group and residual confounding and selection biases that may influence the outcomes in patients undergoing CN. |
Audience | Academic |
Author | Graham, Jeffrey Moria, Feras Ayman Bhindi, Bimal Heng, Daniel Yick Chin Castonguay, Vincent Park, Changsu Lawrence Lalani, Aly-Khan A Wood, Lori Fallah-Rad, Nazanin Ghosh, Sunita Tanguay, Simon Basappa, Naveen S Pouliot, Frederic Finelli, Antonio Bosse, Dominick Saleh, Ramy R Bjarnason, Georg A Kollmannsberger, Christian K Breau, Rodney H |
AuthorAffiliation | 8 Department of Urology, Centre Hospitalier Universitaire de Québec, Université Laval, Québec, QC G1V 0A6, Canada 4 Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada 3 Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 3A7, Canada 2 Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada 9 Department of Surgery, Université Laval, Québec, QC G1V 0A6, Canada 6 Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada 12 Princess Margaret Cancer Centre UHN, Toronto, ON M4W 1H7, Canada 14 Department of Oncology and Hematology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada 7 Hotel Dieu de Quebec, Quebec, QC G1R 2J6, Canada 13 Juravinski Cancer Centre, McMaster University, Hamilton, ON L8S 4L8, Canada; lalania@hhsc.ca 11 Division of Oncology, University of Ottawa, Ottawa, ON K1N 6N5, Canada 5 Southern Alberta Institute of Urology, Calgary, AB T2V 1P9, Canada 1 McGill University Health Centre, McGill University, Montrea |
AuthorAffiliation_xml | – name: 1 McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada; changsu.park@mail.mcgill.ca (C.L.P.) – name: 5 Southern Alberta Institute of Urology, Calgary, AB T2V 1P9, Canada – name: 10 British Columbia Cancer Agency, Vancouver, BC V5Z 3X7, Canada – name: 2 Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada – name: 7 Hotel Dieu de Quebec, Quebec, QC G1R 2J6, Canada – name: 3 Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 3A7, Canada – name: 4 Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada – name: 14 Department of Oncology and Hematology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada – name: 9 Department of Surgery, Université Laval, Québec, QC G1V 0A6, Canada – name: 13 Juravinski Cancer Centre, McMaster University, Hamilton, ON L8S 4L8, Canada; lalania@hhsc.ca – name: 8 Department of Urology, Centre Hospitalier Universitaire de Québec, Université Laval, Québec, QC G1V 0A6, Canada – name: 11 Division of Oncology, University of Ottawa, Ottawa, ON K1N 6N5, Canada – name: 12 Princess Margaret Cancer Centre UHN, Toronto, ON M4W 1H7, Canada – name: 6 Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada |
Author_xml | – sequence: 1 givenname: Changsu Lawrence surname: Park fullname: Park, Changsu Lawrence organization: McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada – sequence: 2 givenname: Feras Ayman surname: Moria fullname: Moria, Feras Ayman organization: McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada – sequence: 3 givenname: Sunita surname: Ghosh fullname: Ghosh, Sunita organization: Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada – sequence: 4 givenname: Lori orcidid: 0000-0003-2405-0216 surname: Wood fullname: Wood, Lori organization: Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 3A7, Canada – sequence: 5 givenname: Georg A orcidid: 0000-0001-6903-5357 surname: Bjarnason fullname: Bjarnason, Georg A organization: Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada – sequence: 6 givenname: Bimal surname: Bhindi fullname: Bhindi, Bimal organization: Southern Alberta Institute of Urology, Calgary, AB T2V 1P9, Canada – sequence: 7 givenname: Daniel Yick Chin surname: Heng fullname: Heng, Daniel Yick Chin organization: Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada – sequence: 8 givenname: Vincent surname: Castonguay fullname: Castonguay, Vincent organization: Hotel Dieu de Quebec, Quebec, QC G1R 2J6, Canada – sequence: 9 givenname: Frederic orcidid: 0000-0002-6651-1079 surname: Pouliot fullname: Pouliot, Frederic organization: Department of Surgery, Université Laval, Québec, QC G1V 0A6, Canada – sequence: 10 givenname: Christian K surname: Kollmannsberger fullname: Kollmannsberger, Christian K organization: British Columbia Cancer Agency, Vancouver, BC V5Z 3X7, Canada – sequence: 11 givenname: Dominick orcidid: 0000-0003-2992-5632 surname: Bosse fullname: Bosse, Dominick organization: Division of Oncology, University of Ottawa, Ottawa, ON K1N 6N5, Canada – sequence: 12 givenname: Naveen S surname: Basappa fullname: Basappa, Naveen S organization: Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada – sequence: 13 givenname: Antonio surname: Finelli fullname: Finelli, Antonio organization: Princess Margaret Cancer Centre UHN, Toronto, ON M4W 1H7, Canada – sequence: 14 givenname: Nazanin surname: Fallah-Rad fullname: Fallah-Rad, Nazanin organization: Princess Margaret Cancer Centre UHN, Toronto, ON M4W 1H7, Canada – sequence: 15 givenname: Rodney H surname: Breau fullname: Breau, Rodney H organization: Division of Oncology, University of Ottawa, Ottawa, ON K1N 6N5, Canada – sequence: 16 givenname: Aly-Khan A orcidid: 0000-0002-9907-9112 surname: Lalani fullname: Lalani, Aly-Khan A organization: Juravinski Cancer Centre, McMaster University, Hamilton, ON L8S 4L8, Canada – sequence: 17 givenname: Simon surname: Tanguay fullname: Tanguay, Simon organization: McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada – sequence: 18 givenname: Jeffrey surname: Graham fullname: Graham, Jeffrey organization: Department of Oncology and Hematology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada – sequence: 19 givenname: Ramy R orcidid: 0000-0001-8265-9316 surname: Saleh fullname: Saleh, Ramy R organization: McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39195334$$D View this record in MEDLINE/PubMed |
BookMark | eNptkttu1DAQhiNURA_wANwgS9xwk2Jn4jjhBlXLaUWhEhRxGU182HUV21vHWWnfhkfF7RbESsiSPRp_889Bc1oc-eB1UTxn9Bygo6_lHGPwMozAaEuBs0fFCROsLYWouqNss64tKeXVcXE6TTeUAgghnhTH0LGOA9Qnxa-l26BMJBhybZ31qztr6dzsQ1rriJsdQa_IYpdC1GqWyW41-ao366hlCm5HrCdfdMIpYbKSfNMeR7LQY74wSuuDwzfZi2P5M8RRkXeYkARPvs9xa7eZvZqTDE5PxMTgSM5JFp8XdroHB5z00-KxwXHSzx7es-LHh_fXi0_l5dXH5eLislQANJWV4ZzCUOsateRAq0bWTHc1a7lqVSfzuHK_KBtjDFUNNEBFqxUy0RgGCHBWLPe6KuBNv4nWYdz1AW1_7whx1WPMLY66R1BSVQNwKbGuWjqYgQ4D40LkBLwxWevtXmszD04rqX2KOB6IHv54u-5XYdszBhyqimeFVw8KMdzOekq9s5PMY0Wvwzz1QDvR8rqBKqMv9-gKc23Wm5Al5R3eX7RU1Ezwus7U-X-ofJR2Vua1Mjb7DwJe_NvD3-L_rA78Bi7gyuc |
ContentType | Journal Article |
Copyright | COPYRIGHT 2024 MDPI AG 2024 by the authors. 2024 |
Copyright_xml | – notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. 2024 |
DBID | CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.3390/curroncol31080351 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1718-7729 |
EndPage | 4712 |
ExternalDocumentID | oai_doaj_org_article_a3dcd2b35cca4280bfb0bb15774ac56f A807417544 39195334 |
Genre | Journal Article |
GeographicLocations | Canada Quebec |
GeographicLocations_xml | – name: Canada – name: Quebec |
GrantInformation_xml | – fundername: Kidney Cancer Research Network of Canada |
GroupedDBID | --- 04C 29F 2WC 53G 5GY 5VS 6PF AAWTL ABDBF ACGFS ADBBV AENEX AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BMSDO CGR CS3 CUY CVF DIK DU5 E3Z EBD EBS ECM EIF EIHBH EJD ESX F5P GROUPED_DOAJ HYE IAO IHR INH ITC KQ8 MODMG NPM OK1 RNS RPM TR2 TUS 7X8 5PM |
ID | FETCH-LOGICAL-d330t-2f5503b4e4aec53026c41e94185d8d9c390334ac6fff0d6363078eda176f13a33 |
IEDL.DBID | RPM |
ISSN | 1198-0052 1718-7729 |
IngestDate | Tue Oct 22 15:06:38 EDT 2024 Tue Sep 17 21:28:05 EDT 2024 Thu Aug 29 22:46:47 EDT 2024 Thu Sep 12 00:36:36 EDT 2024 Tue Sep 10 03:51:40 EDT 2024 Wed Oct 23 09:40:51 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | renal cell carcinoma real-world data CKCis cytoreductive nephrectomy immunotherapy |
Language | English |
License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-d330t-2f5503b4e4aec53026c41e94185d8d9c390334ac6fff0d6363078eda176f13a33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-2405-0216 0000-0002-6651-1079 0000-0001-8265-9316 0000-0003-2992-5632 0000-0001-6903-5357 0000-0002-9907-9112 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353225/ |
PMID | 39195334 |
PQID | 3097854632 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_a3dcd2b35cca4280bfb0bb15774ac56f pubmedcentral_primary_oai_pubmedcentral_nih_gov_11353225 proquest_miscellaneous_3097854632 gale_infotracmisc_A807417544 gale_infotracacademiconefile_A807417544 pubmed_primary_39195334 |
PublicationCentury | 2000 |
PublicationDate | 2024-08-01 |
PublicationDateYYYYMMDD | 2024-08-01 |
PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Current oncology (Toronto) |
PublicationTitleAlternate | Curr Oncol |
PublicationYear | 2024 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
SSID | ssj0033777 |
Score | 2.3916416 |
Snippet | Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive... |
SourceID | doaj pubmedcentral proquest gale pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 4704 |
SubjectTerms | Aged Antimitotic agents Antineoplastic agents Canada Carcinoma, Renal cell Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - surgery CKCis Cytoreduction Surgical Procedures - methods cytoreductive nephrectomy Databases, Factual Female Humans Immunotherapy Immunotherapy - methods Kidney Neoplasms - mortality Kidney Neoplasms - pathology Kidney Neoplasms - surgery Male Medical research Medicine, Experimental Metastasis Middle Aged Nephrectomy - methods Patient outcomes real-world data renal cell carcinoma Treatment Outcome |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDxUXxJuFUhkJiVPUOJM4CbeStmpBLRK0Um-Rn3Sl1kG7yWH_DT-VGSdFG3HgwiWK4kR2PJ_HM_LMN4y9L2wNRenTJMurFB0UkyVK-CyBWinjKp1LHQNkL-TpVf75urjeKvVFMWEjPfA4cQcKrLGZhgK7QlM51V6nWosCzRZlCumj9hXFvTM16mCAshzLqlACWVpk43kmoIN_YIbVqgs4y0DhdUAnlJGt_2-dvLUpzQMmt3agk8fs0WQ68sNxyE_YAxeest3z6XD8Gft1FjMeeef5JdXq-kF3Z5T_MWVZbbgKljcbdLOJsJUUHb9wJE3Td3cbvgz83PWKcoyWhn9z1FvjbvFCBYdCd6c-4lN1m8QIHH6kesW7wL8PqG4QsPzr0CN-3ZpTzgrHPnnzpVmu44u0Wz5nVyfHl81pMhVgSCxA2ieZR_8FdO5y5QyVF5ImF64mvhtb2drgdAKgGKT3PrUSJCqMylklSukFKIAXbCd0wb1iXCIoZCVT1KbogEni3CnLtK6UE5W0tl6wTySE9ufIsdES63V8gFhoJyy0_8LCgn0gEba0NlFORk0pBjgEYrlqD4n5RxDl34Ltzd7ENWVmze_uQdBSEwWiBdcN6xYo74VKCGQL9nIExZ8xQ01nkoBfVzO4zH5q3hKWN5HSW1D5EVStr__HNLxhDzM0vcYwxT22068G9xZNp17vx1XyG-Q-GYw priority: 102 providerName: Directory of Open Access Journals |
Title | Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39195334 https://www.proquest.com/docview/3097854632/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC11353225 https://doaj.org/article/a3dcd2b35cca4280bfb0bb15774ac56f |
Volume | 31 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb5wwELWSHKpeqn6XNo1cqVJPZIEBA72ltFHSatOqTaTckLFNgrRrol047L_pT-2MgSqot14QwiCM_Tz24DdvGHuf6ByStA78KM4CdFBU5MuwjnzIpVQmq2JROYLshTi7ir9eJ9d7TEyxMI60r6rm2K7Wx7a5ddzKu7VaTDyxxY9lEVKyBgTiYp_tpwCTjz7YX4A0HVKqUPBYkETDXiagc79Q_WbTWmxhIGodJJQnBnLaSYJ4FO3_1zTfm5vmvMl7E9HpY_ZoXEHyk6GmT9iesU_Zg-W4R_6M_T53gY-8rfklpey6obNzCgMZg612XFrNix1626TbSvaOXxjqVNW16x1vLF-aTlKoUaP4T0NvK8wKD5R3yLZr-RGvypXviDj8s-wkby3_1aPVQdzy732HMDZbTqErHN_Ji29Fs3U30qT5nF2dfrkszvwxD4OvAYLOj2p0Y6CKTSyNoixDQsWhyUn2Rmc6V9iy2H5SibquAy1AoN3IjJZhKuoQJMALdmBba14xLhAbIhMBGlX0wwRJ76RpkGfShJnQOvfYJ-qE8m6Q2ihJ_NpdaDc35QiBUoJWOqogQfSh9xRUdRVUVZjgSlaqRNQe-0BdWNIQxX5Scow0wCqQ2FV5QgJAISn_eexwdicOLTUrfjeBoKQi4qNZ0_bbEij8hTIJRB57OYDib50nQHksm8Fl9lHzEgS6U_aegP36_x99wx5GuO4aOIqH7KDb9OYtrpu66sj9bzhyg-UPhSQZ4Q |
link.rule.ids | 230,315,733,786,790,870,891,2115,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6VIgEX3oVAgUVC4uTE9tprm1sxVAltAoJU9Gbty8UiWVeJfQi_hp_KjB-ohhNcLMtry17vN7M72m--IeRVqBMWRrnr-EHsQoCifEd4ue-wRAhlYhlw2RBkF3x6Fnw4D8_3CO9zYRrSvpLF2K7WY1t8a7iVl2s16Xlik0_z1MNiDQDEyTVyHQzWD_sovfXAjEVRW1QF08fc0G93MxmE9xNVbzalhX_MkFzHQqwUwxLcS2JBJ9v_t3O-MjsNmZNXpqLjO-Rr34mWgfJ9XFdyrH78oe_47728S253q1N61LbfI3vG3ic35t3--wPyc9YkVdIyp0ssB3aBZzNMMekSuXZUWE3THUTyqAmLvpQuDAJGVeV6RwtL56YSmMZUKPrZ4NtSs4ID1jSy5Vq8gati5TQkH_pOVIKWln6pwaOBTdCPdQUmYrYU02IovJOmJ2mxbW7ECfkhOTt-v0ynTlfjwdGMuZXj5xAiMRmYQBiFFYy4CjyToKSOjnWiYMxgZITieZ67mjMOPik2WngRzz0mGDsg-7a05jGhHHDHY-6Cw4YYj6OsTxS5SSyMF3OtkxF5i8ObXbYyHhkKazcXys1F1v34TDCttC9ZCMiGyMyVuXSl9EJYJQsV8nxEXiM4MjR_QIASXRYDfAIKaWVHKC7koargiBwO7gSzVYPmlz28MmxCrps1Zb3NGKbWYJUCf0QetXD7_c09VEckHgBx0KlhC8CrUQ3v4fTk_x99QW5Ol_PT7HS2OHlKbvmwvmu5kIdkv9rU5hmszyr5vDHGX40NOwk |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BkSouvCmGAouExMmJ7bXXNrfiEjWUhApaqRIHa18uEck6SuxD-DX8VGb8QDXceoks70b2er-Z3dF-8w0hbyOdsiguPDcIEw8CFBW4wi8Cl6VCKJPIkMuGIDvnJxfhp8vosmNVbjtapVVyMbLL1cgufjTcyvVKjXue2PhslvlYrAGAOF7rYnyb3AGjDeI-Um-9MGNx3BZWwRQyLwraE00GIf5Y1ZtNaeE7MyTYsQirxbAUz5NY2En3_--gr61QQ_bkteVocp987wfSslB-jupKjtSvfzQebzbSB-Ret0ulR22fh-SWsY_I_qw7h39Mfk-b5EpaFvQcy4Jd4dUUU026hK4dFVbTbAcRPWrDok-lc4PAUVW52tGFpTNTCUxnWij61eDTMrOEH6xtZMuVeA93xdJtyD70WFSClpZ-q8GzgW3QL3UFpmK2FNNjKDyTZqfZYtt0xIX5CbmYfDzPTtyu1oOrGfMqNyggVGIyNKEwCisZcRX6JkVpHZ3oVMG8wewIxYui8DRnHHxTYrTwY174TDD2lOzZ0ppnhHLAH0-4B44bYj2O8j5x7KWJMH7CtU4d8gGnOF-3ch45Cmw3N8rNVd59_FwwrXQgWQQIhwjNk4X0pPQj2C0LFfHCIe8QIDm6AUCBEl02A7wCCmrlRygy5KO6oEMOBz3BfNWg-U0PsRybkPNmTVlvc4YpNlitIHDIQQu5v-_cw9UhyQCMg0ENWwBijXp4D6nnN__ra7J_djzJP0_npy_I3QC2eS0l8pDsVZvavIRtWiVfNfb4B05oPYk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+Timing+of+Immunotherapy+and+Cytoreductive+Nephrectomy+in+Metastatic+Renal+Cell+Carcinoma%3A+Real-World+Data+on+Survival+Outcomes+from+the+CKCis+Database&rft.jtitle=Current+oncology+%28Toronto%29&rft.au=Changsu+Lawrence+Park&rft.au=Feras+Ayman+Moria&rft.au=Sunita+Ghosh&rft.au=Lori+Wood&rft.date=2024-08-01&rft.pub=MDPI+AG&rft.issn=1198-0052&rft.eissn=1718-7729&rft.volume=31&rft.issue=8&rft.spage=4704&rft.epage=4712&rft_id=info:doi/10.3390%2Fcurroncol31080351&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_a3dcd2b35cca4280bfb0bb15774ac56f |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1198-0052&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1198-0052&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1198-0052&client=summon |